Literature DB >> 21125490

Promises and challenges in developing RNAi as a research tool and therapy.

Mouldy Sioud1.   

Abstract

Small interfering RNA (siRNAs), the main effector of RNA interference (RNAi), are now routinely used to assess gene function, both in vitro and in vivo, and many innovative screens have been reported on the use of RNAi to identify potential drug targets. Despite several technical advances, however, there are still many challenges in determining the ideal design of siRNA sequence, the activation of the immune system, off-target effects, and competition with endogenous microRNAs for cellular miRNA-processing machinery. Therefore, the translation of RNAi technology into the clinic depends on resolving these challenges. This chapter summarizes recent progress in siRNA design, sensing by the immune system, and discusses some of the promising approaches that are currently being explored in separating siRNA unwanted effects from gene silencing.

Mesh:

Substances:

Year:  2011        PMID: 21125490     DOI: 10.1007/978-1-59745-248-9_12

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  15 in total

Review 1.  RNAi screening: new approaches, understandings, and organisms.

Authors:  Stephanie E Mohr; Norbert Perrimon
Journal:  Wiley Interdiscip Rev RNA       Date:  2011-09-22       Impact factor: 9.957

2.  Survivin inhibition by an interacting recombinant peptide, derived from the human ferritin heavy chain, impedes tumor cell growth.

Authors:  Astrid Weiss; Boris Brill; Corina Borghouts; Natalia Delis; Laura Mack; Bernd Groner
Journal:  J Cancer Res Clin Oncol       Date:  2012-03-18       Impact factor: 4.553

3.  Survivin expression in human lung cancer and the influence of its downregulation on the biological behavior of human lung cancer cells.

Authors:  Xiang-Qi Chen; Sheng Yang; Ming-Qiang Kang; Zhi-Ying Li; Hui-Shan Lu; Ting-Yan Lin
Journal:  Exp Ther Med       Date:  2012-03-23       Impact factor: 2.447

4.  Inhibition of polo-like kinase 1 in glioblastoma multiforme induces mitotic catastrophe and enhances radiosensitisation.

Authors:  Anita T Tandle; Tamalee Kramp; Whoon J Kil; Aditya Halthore; Kristen Gehlhaus; Uma Shankavaram; Philip J Tofilon; Natasha J Caplen; Kevin Camphausen
Journal:  Eur J Cancer       Date:  2013-06-18       Impact factor: 9.162

Review 5.  Genetic analysis of neuronal ionotropic glutamate receptor subunits.

Authors:  Adam J Granger; John A Gray; Wei Lu; Roger A Nicoll
Journal:  J Physiol       Date:  2011-07-18       Impact factor: 6.228

Review 6.  New approaches for understanding mechanisms of drug resistance in schistosomes.

Authors:  Robert M Greenberg
Journal:  Parasitology       Date:  2013-04-03       Impact factor: 3.234

7.  A bidirectional system for the dynamic small molecule control of intracellular fusion proteins.

Authors:  Taavi K Neklesa; Devin J Noblin; Alexander P Kuzin; Scott Lew; Jayaraman Seetharaman; Thomas B Acton; Gregory J Kornhaber; Rong Xiao; Gaetano Thomas Montelione; Liang Tong; Craig M Crews
Journal:  ACS Chem Biol       Date:  2013-08-26       Impact factor: 5.100

8.  Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers.

Authors:  Kristina W Thiel; Luiza I Hernandez; Justin P Dassie; William H Thiel; Xiuying Liu; Katie R Stockdale; Alissa M Rothman; Frank J Hernandez; James O McNamara; Paloma H Giangrande
Journal:  Nucleic Acids Res       Date:  2012-03-30       Impact factor: 16.971

9.  5-alpha-reductase type I (SRD5A1) is up-regulated in non-small cell lung cancer but does not impact proliferation, cell cycle distribution or apoptosis.

Authors:  Friedrich G Kapp; Anette Sommer; Thomas Kiefer; Gottfried Dölken; Bernard Haendler
Journal:  Cancer Cell Int       Date:  2012-01-18       Impact factor: 5.722

10.  Iodine-131 dose dependent gene expression in thyroid cancers and corresponding normal tissues following the Chernobyl accident.

Authors:  Michael Abend; Ruth M Pfeiffer; Christian Ruf; Maureen Hatch; Tetiana I Bogdanova; Mykola D Tronko; Armin Riecke; Julia Hartmann; Viktor Meineke; Houda Boukheris; Alice J Sigurdson; Kiyohiko Mabuchi; Alina V Brenner
Journal:  PLoS One       Date:  2012-07-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.